ArticleOncotarget2018
Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets.BMC cancer · 2020Pooled it
- A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (humPcMab-60) Demonstrated Antitumor Efficacy in Pancreatic and Colorectal Cancer Xenograft Models.Antibodies (Basel, Switzerland) · 2025Article
- Development of chimeric antigen receptor T cells targeting cancer-expressing podocalyxin.Regenerative therapy · 2025Article
- A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.International journal of molecular sciences · 2023Article
- Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody CAntibodies (Basel, Switzerland) · 2023Article
- A Novel Anti-CD44 Variant 9 Monoclonal Antibody CCurrent issues in molecular biology · 2023Article
- Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody CCurrent issues in molecular biology · 2023Article
- Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody CInternational journal of molecular sciences · 2023Article
- Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function.Science advances · 2023Article
- Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.International journal of molecular medicine · 2023Article
- RIOK2 Contributes to Cell Growth and Protein Synthesis in Human Oral Squamous Cell Carcinoma.Current oncology (Toronto, Ont.) · 2022Article
- A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mGAntibodies (Basel, Switzerland) · 2022Article
- Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma.Pharmaceutics · 2022Article
- Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.Oncology reports · 2022Article
- Article
- Glycan array analysis of Pholiota squarrosa lectin and other fucose-oriented lectins.Glycobiology · 2021Article
- A defucosylated anti-PD-L1 monoclonal antibody 13-mGBiochemistry and biophysics reports · 2020Article
- Anti‑EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas.Oncology reports · 2020Article
- A cancer-specific anti-podocalyxin monoclonal antibody (60-mGBiochemistry and biophysics reports · 2020Article
- A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.Oncology reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Podocalyxin (PODXL) overexpression is associated with progression, metastasis, and poor outcomes in cancers. We recently produced the novel anti-PODXL monoclonal antibody (mAb) PcMab-47 (IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.